Long-term outcomes and predictors of percutaneous radiofrequency thermocoagulation of Gasserian ganglion for maxillary trigeminal neuralgia: a retrospective analysis of 1070 patients with minimum 2-year follow-up

OBJECTIVE

To estimate long-term efficacy and safety for maxillary trigeminal neuralgia (TN) using radiofrequency thermocoagulation (RFT) targeted on Gasserian ganglion, and to identify the factors which may influence outcomes after procedure.

METHODS

From 2006 to 2019, 1070 patients underwent RFT for the treatment of medically refractory maxillary TN was included. All patients were followed up for at least 2 years. Outcomes and complications were recorded and analysed. Logistic regression analysis was employed to identify risk factors of long-term pain recurrence. Prognostic value was calculated from receiver-operating characteristic curve (ROC).

RESULTS

Longitudinal analysis was taken place for 97 non-responders (9.1%) with ineffective pain relief, 253 responders (23.6%) with pain recurrence and 720 responders (67.3%) without pain recurrence. The median pain-free survival (PFS) was 112.0 months (95% CI: 107.5, 116.5). The pain-free rates were 89.9% (95% CI: 88.0-91.8%) at 1 year, 83.8% (95% CI: 81.5-86.1%) at 2 years, 75.4% (95% CI: 72.7-78.1%) at 5 years and 70.2% (95% CI: 67.4-73.0%) at 10 years. Atypical facial pain (HR = 5.373, 95% CI: 2.623-11.004, p < .001), previous facial numbness (HR = 5.224, 95% CI: 3.107-8.784, p < .001) and poor initial response to medication (HR = 3.185, 95% CI: 2.087-4.860, p < .001) were independently associated with long-term pain recurrence. Patients with prognostic index (PI) > 0.25 were identified as high-risk for recurrent TN (HR = 5.575, 95% CI: 3.991-7.788, p < .001). New and worsen facial hypoesthesia was recorded in 77.9% of patients corresponding with BNI score II-IV, and 18.7% reported improved sensation. Severe complication incidence including troublesome dysesthaesia, keratitis and masseter weakness was higher in 80 °C group.

CONCLUSIONS

Favourable outcomes were achieved in terms of long-term pain relief and complications rate after RFT for maxillary TN. Patients with typical facial pain, normal facial sensation, and good initial response to medications may have favourable long-term outcomes.Key messagesThis is a retrospective analysis of radiofrequency thermocoagulation (RFT) targeted on Gasserian ganglion for the treatment of maxillary trigeminal neuralgia (TN) during long-term follow-up. Recurrence-free survival among a large sample was assessed and risk factors associated with long-term pain recurrence was identified. It has been verified that inadvertent damage of ophthalmic and mandibular division causes ophthalmic and masticatory complications. Therefore, a more precise needle tip position and thermocoagulation using a relatively low temperature was recommended.

Long-term Recurrence-free Survival and Complications of Percutaneous Balloon Compression and Radiofrequency Thermocoagulation of Gasserian Ganglion for Trigeminal Neuralgia:A Retrospective Study of 1313 Cases

OBJECTIVE

To estimate long-term recurrence, complications after percutaneous balloon compression (PBC) and radiofrequency thermocoagulation (RFT) of gasserian ganglion among a large sample of patients with trigeminal neuralgia (TN) during a long-term follow-up.

METHODS

A retrospective analysis of 1313 patients undergoing PBC or RFT for the treatment of TN was conducted from 2006 to 2020. Recurrence-free survival (RFS) was assessed by Kaplan-Meier method. Complications including facial numbness, corneal reflex decrease and masseter weakness were also estimated.

RESULTS

For patients who received first initial PBC and RFT, the median RFS was 130.1 months (95%CI: 124.4, 135.9) and 123.3 months (95%CI: 117.6, 128.9) in PBC and RFT group with log-rank p=0.108. The RFS rate was respectively 90.6% (95%CI: 88.1%-93.3%) and 91.4% (95%CI: 89.1%-93.7%) at 1 year, 84.6% (95%CI: 81.4%-87.8%) and 83.3% (95%CI: 80.3%-86.3%) at 3 years, 81.5% (95%CI: 78.1%-85.0%) and 78.6 % (95%CI: 75.2%-81.9%) at 5 years, 71.5% (95%CI: 67.5%-75.5%) and 64.8% (95%CI: 61.0%-68.7%) at 10 years in two groups. No significant difference was observed in facial numbness degree between two groups after procedure. Compared with PBC group, ophthalmic complication prevalence was higher in RFT group (9.6%) (p=0.001). However, masseter weakness incidence was lower (10.7%) than that in PBC group (24.0%) with p<0.001.

CONCLUSIONS

Patients with TN seemed to attain similar long-term benefit from PBC and RFT, especially in elderly. However, in order to reduce postoperative complications, PBC provided a safer and alternative for treating TN involving ophthalmic division, whereas RFT could be employed as a preferred regimen for maxillary and mandibular TN.